Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07292389 · ClinicalTrials.gov registry record · NA
Examining Valence-based Effects in Self-Monitoring Feedback Messages
A NA study, sponsored by University of Virginia.
- Recruiting
- Registry status
- NA
- Development phase
- 127
- Enrollment target
NCT07292389: Recruiting NA study, sponsored by University of Virginia.
NCT07292389 is a NA study that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 127 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07292389, a NA study, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- NA
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn how to identify the most effective ways to provide weekly feedback on participants' progress toward intervention goals during a weight loss program.
Primary Outcome
Mixed-effects models will be used to investigate the impact of each feedback condition on our primary outcome of weight change. Fitted model estimates will be used to calculate the slope of weight change from day 1 (the day a feedback message is delivered) through day 7 of each week. Positive slopes indicate weight gain, while negative slopes indicate weight loss.
Interventions
- BEHAVIORAL Positive Reinforcement
- BEHAVIORAL Positive Reinforcement + Areas for Change
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT07292389 shows while recruiting
NCT07292389 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Positive Reinforcement is the first listed.
NCT07292389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07292389 about?
NCT07292389 is a clinical study titled "Examining Valence-based Effects in Self-Monitoring Feedback Messages". The purpose of this research study is to learn how to identify the most effective ways to provide weekly feedback on participants' progress toward intervention goals during a weight loss program.
What is the current status of trial NCT07292389?
This trial is currently recruiting. It is a NA study. The enrollment target is 127 participants. The study started on 2026-03-23. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07292389?
The interventions under investigation include: Positive Reinforcement (BEHAVIORAL), Positive Reinforcement + Areas for Change (BEHAVIORAL).
Who is sponsoring clinical trial NCT07292389?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07292389's enrollment target sits among peer trials
127 749th of 2000 higher than 1,252 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI